Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Propoxycaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 6/20 | 0.66 |
| ▸ | SCN2A known ✓ | Q99250 | 6/20 | 0.66 |
| ▸ | SCN3A known ✓ | Q9NY46 | 6/20 | 0.66 |
| ▸ | SCN5A known ✓ | Q14524 | 2/20 | 0.61 |
| ▸ | SCN7A known ✓ | Q01118 | 1/20 | 0.61 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.61 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.61 |
| ▸ | MAOA | P21397 | 4/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propoxycaine SCHEMBL1286868 | 0.99 | SCN1A (0.67) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Propoxycaine SCHEMBL6135188 | 0.98 | SCN1A (0.68) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Tetracaine SCHEMBL1429149 | 0.88 | LMNA (0.79) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Proparacaine SCHEMBL21461268 | 0.86 | SCN1A (0.70) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Proparacaine SCHEMBL20704827 | 0.85 | SCN1A (0.71) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Propoxycaine SCHEMBL8683800 | 0.83 | CYP1A2 (0.83) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Propoxycaine SCHEMBL24720 | 0.82 | SCN1A (0.98) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Ambucaine SCHEMBL1007224 | 0.82 | CYP2D6 (0.88) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Propoxycaine SCHEMBL83073 | 0.81 | SCN1A (1.00) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 | |
| Propoxycaine SCHEMBL29353209 | 0.81 | SCN1A (1.00) | CYP1A2SCN1ASCN2ASCN3ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985736-B2 | Therapeutic mixture comprising voltage gated calcium channel modulator for use in treatment and prevention of infertility, cancer, diabetes and behavioral disorders | THE JOHN HOPKINS UNIVERSITY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080279864-A1 | High Throughput Screen Utilizing Newly Discovered Intramolecular Neuronal Calcium Channel Interactions To Discover New Analgesics | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2006066110-A2 | Cav2 RELATED COMPOSITIONS AND METHODS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-1613324-A2 | METHODS FOR THE TREATMENT OF PAIN COMPRISING OPIOID ANTAGONISTS | Pain Therapeutics, Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050038062-A1 | Methods and materials for the treatment of pain comprising opioid antagonists | PAIN THERAPEUTICS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004091593-A2 | METHODS FOR THE TREATMENT OF PAIN COMPRISING OPIOID ANTAGONISTS | PAIN THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |